Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRM1 | P35372 | 6/20 | 0.44 |
| ▸ | OPRD1 | P41143 | 6/20 | 0.44 |
| ▸ | TP53 | P04637 | 2/20 | 0.32 |
| ▸ | CTSD | P07339 | 1/20 | 0.32 |
| ▸ | BCHE | P06276 | 1/20 | 0.30 |
| ▸ | POLB | P06746 | 1/20 | 0.30 |
| ▸ | ATM | Q13315 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL490331 | 0.70 | OPRD1 (0.53) | OPRM1OPRD1TP53 | |
| SCHEMBL21135535 | 0.70 | MAPT (0.54) | OPRM1ATM | |
| SCHEMBL27794501 | 0.66 | SRD5A2 (0.58) | ATM | |
| SCHEMBL6530674 | 0.65 | OPRM1 (0.40) | OPRM1OPRD1TP53 | |
| SCHEMBL490658 | 0.65 | OPRD1 (0.42) | OPRM1OPRD1 | |
| SCHEMBL7681194 | 0.65 | ALDH1A1 (0.44) | BCHEPOLBATM | |
| SCHEMBL23648301 | 0.64 | TRPA1 (0.53) | TP53POLBATM | |
| SCHEMBL10848340 | 0.64 | HDAC8 (0.41) | BCHEPOLBATM | |
| SCHEMBL28317759 | 0.63 | TP53 (0.53) | TP53 | |
| Thioxanthene SCHEMBL11865022 | 0.62 | ALDH1A1 (0.53) | BCHEATM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120095010-A1 | TRICYCLIC DELTA-OPIOID MODULATORS | CARSON JOHN R (US) | 2012-04-19 | — | — | US | disclosed |
| US-8106207-B2 | Tricyclic δ-opioid modulators | JANSSEN PHARMACEUTICA, NV (BE) | 2012-01-31 | — | — | US | disclosed |
| US-20110245291-A1 | TRICYCLIC DELTA-OPIOID MODULATORS | CARSON JOHN R | 2011-10-06 | — | — | US | disclosed |
| US-7982042-B2 | delta-opioid receptor agonists as analgesics having reduced side effects and antagonists as immunosuppressants, antiinflammatory agents, neurological, psychiatric , urological and reproductive conditions;N-{2-[10-(8-Allyl-8-aza-bicyclo[3.2.1]oct-3-yl)-10H-phenothiazine-3-yl]-phenyl}-acetamide | Janseen Pharmacautica NV (BE) | 2011-07-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120095010-A1 | TRICYCLIC DELTA-OPIOID MODULATORS | OPRD1, OPRK1, OPRL1 | OPRM1 4/4885OPRD1 1/4885TP53 4774/4885 |
| US-20110245291-A1 | TRICYCLIC DELTA-OPIOID MODULATORS | OPRD1, OPRK1, OPRL1 | OPRM1 4/4885OPRD1 1/4885TP53 4774/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.